Quantcast
Last updated on April 17, 2014 at 12:39 EDT

Latest Sulfonylureas Stories

2013-12-05 23:48:03

No data on patients with metformin intolerance or contraindication The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus. It is an option when drug treatment is needed, but the drug metformin is not tolerated or cannot be used. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency...

2013-09-25 08:30:55

WOODCLIFF LAKE, N.J., Sept. 25, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for glipizide 5 mg and 10 mg extended-release (ER) tablets. Glipizide ER is the generic version of Pfizer's Glucotrol XL(®) and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Par has begun...

2013-06-06 11:37:43

Manufacturer's dossier did not contain suitable data for any therapeutic indication Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. No such...

2013-04-29 16:01:28

Drug manufacturer did not submit suitable data in its dossier The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products” (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this fixed combination product offers an added...

2012-06-25 21:12:15

Compared to another popular drug, three widely used diabetes medications are associated with a greater risk of death, a large new analysis finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston. The drugs, glipizide, glyburide, and glimepiride, are known as sulfonylureas, which help decrease blood-sugar levels among type 2 diabetes patients by stimulating the pancreas to produce insulin. In the past, these medications were considered...

2012-06-09 06:21:37

PHILADELPHIA, June 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) presented results from five Phase 3 clinical studies evaluating canagliflozin in monotherapy and in add-on combination use showing that canagliflozin provided substantial and sustained glycemic improvements in adult patients with type 2 diabetes, and was generally well tolerated. In two of these studies comparing canagliflozin to current standard treatments, sitagliptin and glimepiride, canagliflozin...

2012-06-09 06:21:21

RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin at the American Diabetes Association's (ADA's) 72nd Scientific Sessions®. The new studies provide additional data evaluating the efficacy and safety of linagliptin (alone or in combination with other diabetes therapies) in adults with type 2...

2012-02-28 10:31:53

University of Michigan leads study showing TAK-875 helps control blood sugar in type 2 diabetes by boosting insulin TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study. The results of the phase 2 randomized trial were published Online First Sunday in The Lancet. Type 2 diabetes is the most common...

2012-01-06 14:45:41

Drug manufacturer deviates from appropriate comparator therapy specified by the G-BA Linagliptin (trade name: Trajenta®) has been approved since August 2011 to improve blood glucose control ("glycaemic control") in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise. It is an option for patients who do not tolerate or should not take the usual treatment with the drug metformin. Moreover, linagliptin can be added if...

2011-06-28 11:45:00

DEERFIELD, Ill. and OSAKA, Japan, June 28, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that results from late breaking data presented by Takeda Global Research & Development Center, Inc. evaluated the safety, tolerability and hemoglobin A1c (HbA1c) lowering activity for TAK-875, an investigational compound for the treatment of type 2 diabetes, at the American Diabetes Association (ADA) 71st Annual Scientific Sessions in San Diego, California....